Journal
CARDIOLOGY IN REVIEW
Volume 20, Issue 2, Pages 53-65Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/CRD.0b013e31823efde2
Keywords
Trypanosoma cruzi; Chagas disease; nifurtimox; benznidazole; heart transplantation; echocardiogram; cardiac magnetic resonance imaging
Categories
Funding
- NIH [HL-73732, AI-076248, CA123334, AI062730]
- Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq) [576200/2008-5, 473670/2008-9]
- Fundacao de Amparo a Pesquisa do Estado de Minas Gerais (FAPEMIG) [14916]
- Fogarty International Training Grant [D43TW007129]
Ask authors/readers for more resources
Chagas disease, caused by the parasite Trypanosoma cruzi, is an important cause of cardiac disease in endemic areas of Latin America. It is now being diagnosed in nonendemic areas because of immigration. Typical cardiac manifestations of Chagas disease include dilated cardiomyopathy, congestive heart failure, arrhythmias, cardioembolism, and stroke. Clinical and laboratory-based research to define the pathology resulting from T. cruzi infection has shed light on many of the cellular and molecular mechanisms leading to these manifestations. Antiparasitic treatment may not be appropriate for patients with advanced cardiac disease. Clinical management of Chagas heart disease is similar to that used for cardiomyopathies caused by other processes. Cardiac transplantation has been successfully performed in a small number of patients with Chagas heart disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available